The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer

被引：3
作者：
Murphy, Adrian G. [1 ]
Kelly, Ronan J. [1 ]
机构：
[1] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg,1650 Orleans St, Baltimore, MD 21231 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2017年 / 31卷 / 03期
关键词：
Immune checkpoint; Immunotherapy; Programmed death-1; Cytotoxic T lymphocyte associated protein-4; Pembrolizumab; Nivolumab; BARRETTS-ESOPHAGUS; GASTRIC-CANCER; PHASE-III; OPEN-LABEL; EXPRESSION; CISPLATIN; SAFETY; PLUS; FLUOROURACIL; INFILTRATION;
D O I：
10.1016/j.hoc.2017.01.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.
引用
收藏
页码：485 / +
页数：16
相关论文
共 31 条
  • [1] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
    Al-Batran, Salah-Eddin
    Hartmann, Joerg Thomas
    Probst, Stephan
    Schmalenberg, Harald
    Hollerbach, Stephan
    Hofheinz, Ralf
    Rethwisch, Volker
    Seipelt, Gernot
    Homann, Nils
    Wilhelm, Gerhard
    Schuch, Gunter
    Stoehlmacher, Jan
    Derigs, Hans Guenter
    Hegewisch-Becker, Susanna
    Grossmann, Johannes
    Pauligk, Claudia
    Atmaca, Akin
    Bokemeyer, Carsten
    Knuth, Alexander
    Jaeger, Elke
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1435 - 1442
  • [2] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [3] [Anonymous], ACTA HISTOCHEM
  • [4] [Anonymous], J CLIN ONCOL S4S
  • [5] [Anonymous], GUT
  • [6] Ayers M, 2015, J IMMUNOTHER CANCER, V3, P80, DOI DOI 10.1186/2051-1426-3-S2-P80
  • [7] Comprehensive molecular characterization of gastric adenocarcinoma
    Bass, Adam J.
    Thorsson, Vesteinn
    Shmulevich, Ilya
    Reynolds, Sheila M.
    Miller, Michael
    Bernard, Brady
    Hinoue, Toshinori
    Laird, Peter W.
    Curtis, Christina
    Shen, Hui
    Weisenberger, Daniel J.
    Schultz, Nikolaus
    Shen, Ronglai
    Weinhold, Nils
    Keiser, David P.
    Bowlby, Reanne
    Sipahimalani, Payal
    Cherniack, Andrew D.
    Getz, Gad
    Liu, Yingchun
    Noble, Michael S.
    Pedamallu, Chandra
    Sougnez, Carrie
    Taylor-Weiner, Amaro
    Akbani, Rehan
    Lee, Ju-Seog
    Liu, Wenbin
    Mills, Gordon B.
    Yang, Da
    Zhang, Wei
    Pantazi, Angeliki
    Parfenov, Michael
    Gulley, Margaret
    Piazuelo, M. Blanca
    Schneider, Barbara G.
    Kim, Jihun
    Boussioutas, Alex
    Sheth, Margi
    Demchok, John A.
    Rabkin, Charles S.
    Willis, Joseph E.
    Ng, Sam
    Garman, Katherine
    Beer, David G.
    Pennathur, Arjun
    Raphael, Benjamin J.
    Wu, Hsin-Ta
    Odze, Robert
    Kim, Hark K.
    Bowen, Jay
    [J]. NATURE, 2014, 513 (7517) : 202 - 209
  • [8] Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
    Derks, Sarah
    Nason, Katie S.
    Liao, Xiaoyun
    Stachler, Matthew D.
    Liu, Kevin X.
    Bin Liu, Jie
    Sicinska, Ewa
    Goldberg, Michael S.
    Freeman, Gordon J.
    Rodig, Scott J.
    Davison, Jon M.
    Bass, Adam J.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1123 - 1129
  • [9] Inflammatory gradient in Barrett's oesophagus: implications for disease complications
    Fitzgerald, RC
    Abdalla, S
    Onwuegbusi, BA
    Sirieix, P
    Saeed, IT
    Burnham, WR
    Farthing, MJG
    [J]. GUT, 2002, 51 (03) : 316 - 322
  • [10] Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Van Cutsem, Eric
    Wang, Jiang Dian
    Lam, Baohoang
    Dalal, Rita
    Koshiji, Minori
    Bang, Yung-Jue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1234